Contact information
Research groups
Sarah Gooding
Clinician Scientist
The genetics of drug resistance and poor outcomes in multiple myeloma
My research interest is to better understand why the bone marrow cancer multiple myeloma remains incurable, despite novel therapy availability in recent years, and to translate this understanding into better outcomes for our patients.
I joined the Chapman group in 2021 to focus on the interaction between genome instability and poor outcomes in Multiple Myeloma. I have worked in the WIMM since 2013, during my DPhil in the Drakesmith group (HIU) and postdoc in the Vyas group. I am also an honorary consultant specialising in myeloma in Oxford University Hospitals Haematology department.
While myeloma usually initially responds well to combination treatments of novel agents, such as IMiDs or proteosome inhibitors, and chemotherapy, over time it inevitably develops resistance to the drugs we have available, and becomes more aggressive, meaning it is largely incurable. I work on the genetics of drug resistance, and the clonal competition within a tumour that leads to more difficult-to-treat disease emerging. I am interested in how instability within the cancer genome speeds up this process.
I am also interested in how to better utilise cancer genetic analysis in patient care, both for myeloma patients and more widely, so that the information contained in a cancer genome can be used to direct therapeutic choices and maximise better outcomes for patients.
Key publications
-
Journal article
Gooding S. et al, (2020), Blood
-
Journal article
Gooding S. et al, (2019), Nat Commun, 10
Recent publications
-
Precision medicine for liver tumours with quantitative MRI and whole genome sequencing (Precision1 trial): study protocol for observational cohort study.
Journal article
Welsh FK. et al, (2022), BMJ open, 12
-
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response.
Journal article
Ramasamy K. et al, (2022), Br J Haematol
-
Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways.
Journal article
Karagoz K. et al, (2022), Frontiers in genetics, 13
-
COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma.
Journal article
Ramasamy K. et al, (2021), Br J Haematol
-
Myeloma clinical outcomes following the first wave of COVID-19: results from the Thames Valley Cancer Alliance (UK).
Journal article
Sharpley FA. et al, (2020), Br J Haematol